DE69923081D1 - Desmethylolanzapine enthaltende zusammensetzungen und verfahren - Google Patents

Desmethylolanzapine enthaltende zusammensetzungen und verfahren

Info

Publication number
DE69923081D1
DE69923081D1 DE69923081T DE69923081T DE69923081D1 DE 69923081 D1 DE69923081 D1 DE 69923081D1 DE 69923081 T DE69923081 T DE 69923081T DE 69923081 T DE69923081 T DE 69923081T DE 69923081 D1 DE69923081 D1 DE 69923081D1
Authority
DE
Germany
Prior art keywords
desmethylolanzapine
disorder
olanzapine
treatment
containing compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69923081T
Other languages
English (en)
Other versions
DE69923081T2 (de
Inventor
William E Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of DE69923081D1 publication Critical patent/DE69923081D1/de
Application granted granted Critical
Publication of DE69923081T2 publication Critical patent/DE69923081T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69923081T 1998-11-23 1999-11-22 Desmethylolanzapine enthaltende zusammensetzungen und verfahren Expired - Fee Related DE69923081T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10958498P 1998-11-23 1998-11-23
US109584P 1998-11-23
PCT/US1999/027647 WO2000030650A1 (en) 1998-11-23 1999-11-22 Desmethylolanzapine compositions and methods

Publications (2)

Publication Number Publication Date
DE69923081D1 true DE69923081D1 (de) 2005-02-10
DE69923081T2 DE69923081T2 (de) 2005-12-08

Family

ID=22328453

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923081T Expired - Fee Related DE69923081T2 (de) 1998-11-23 1999-11-22 Desmethylolanzapine enthaltende zusammensetzungen und verfahren

Country Status (10)

Country Link
US (2) US6348455B1 (de)
EP (1) EP1133300B1 (de)
JP (1) JP2002530341A (de)
AT (1) ATE286398T1 (de)
AU (1) AU757973B2 (de)
CA (1) CA2351718A1 (de)
DE (1) DE69923081T2 (de)
ES (1) ES2237188T3 (de)
PT (1) PT1133300E (de)
WO (1) WO2000030650A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
PL199016B1 (pl) 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
US6831077B2 (en) * 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
CA2529857A1 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
US7763660B2 (en) * 2003-02-05 2010-07-27 The University Of Vermont And State Agricultural College Inhibitors of Candida albicans
PL198589B1 (pl) 2004-11-22 2008-06-30 Adamed Sp Z Oo Sposób wytwarzania N-demetyloolanzapiny
US20060194769A1 (en) * 2005-01-25 2006-08-31 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2009014770A2 (en) * 2007-02-01 2009-01-29 Green Alan I Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EP0852496A4 (de) 1995-09-29 1998-11-11 Lilly Co Eli Verfahren zur behandlung des ticks
JP2000502346A (ja) 1995-12-21 2000-02-29 イーライ・リリー・アンド・カンパニー 皮膚炎の処置方法
NZ325036A (en) 1995-12-22 2001-06-29 Lilly Co Eli Method for treating depression
UA57727C2 (uk) 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CN1213970A (zh) 1996-03-11 1999-04-14 伊莱利利公司 治疗孤独癖的方法
WO1997033577A1 (en) 1996-03-11 1997-09-18 Eli Lilly And Company Method for treating bipolar disorder
CN1213308A (zh) 1996-03-11 1999-04-07 伊莱利利公司 治疗精神性药物滥用的方法
GB9615767D0 (en) 1996-07-26 1996-09-04 Smithkline Beecham Plc Novel treatment

Also Published As

Publication number Publication date
WO2000030650A1 (en) 2000-06-02
JP2002530341A (ja) 2002-09-17
AU757973B2 (en) 2003-03-13
AU1741600A (en) 2000-06-13
US6348455B1 (en) 2002-02-19
US20020082251A1 (en) 2002-06-27
US6468997B2 (en) 2002-10-22
DE69923081T2 (de) 2005-12-08
ES2237188T3 (es) 2005-07-16
EP1133300A1 (de) 2001-09-19
CA2351718A1 (en) 2000-06-02
EP1133300B1 (de) 2005-01-05
ATE286398T1 (de) 2005-01-15
PT1133300E (pt) 2005-04-29

Similar Documents

Publication Publication Date Title
DE69923081D1 (de) Desmethylolanzapine enthaltende zusammensetzungen und verfahren
DE69912635D1 (de) Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
BRPI0413022A (pt) derivados de 3-amino cromado e 2-amino tetralina
FI963294A (fi) Naftyyliamidit keskushermostoaineina
DE69402352T2 (de) Diamant/Kohlenstoff/Kohlenstoff-Verbundwerkstoff, verwendbar als integrales dielektrisches Kühlblech, und Verfahren zu seiner Herstellung
BRPI0402420A (pt) Processos de toner
ATE304556T1 (de) Verfahren zur herstellung von amorphen alpha- olefinpolymeren, diese enthaltende zusammensetzungen und verfahren zur herstellung von verbrückten liganden
ATE427532T1 (de) Verfahren und vorrichtung fur hierarchische layout spezialisierung
DE60107904D1 (de) Gerät und Verfahren zur automatischen Erzeugung von Schaltungen, und Rechnerprogrammprodukt zur Ausführung des Verfahrens
DE69624976T2 (de) Verfahren zur Herstellung von MOS-Leistungstransistoren
DE69528484D1 (de) Schicht zur Verteilung von Flüssigkeit in absorbierenden Artikeln
DE60001935T2 (de) Verfahren zur schnellen kristallisation von polyestern und copolyestern durch in-linie strecken und strömungsinduzierte kristallisation
ES2188760T3 (es) Oligonucleotidos especificos para el virus de la hepatitis b.
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE69300609D1 (de) Syndiotaktischen Polypropylen, Wachs, Verfahren zur Herstellung derselbe und ihre Anwendung in eine Wärmefixiertonerzusammensetzung für geheizte Walze.
ATE332367T1 (de) Verfahren zur übertragung ausgewählter moleküle
DE10295664D2 (de) Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Paptide und deren Verwendungen
DE60027077D1 (de) Reinigungszusammensetzung zur Behandlung und/oder Verbesserung von Schuppen, Dermatitis seborrhoeica, Psoriasis und Ekzemen und deren Symptomen
DE60231507D1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
DE60307830D1 (de) Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln
ATE519859T1 (de) Verfahren zur herstellung von ausgewählten intermolekularen quervernetzungen in nukleinsäuren und ihre verwendungen
PT1047449E (pt) Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal
ATA190497A (de) Verfahren zur herstellung von direkt reduziertem eisen, flüssigem roheisen und stahl sowie anlage zur durchführung des verfahrens
Lee et al. Effects of School Safety Education on Safety Behavior among Elementary School Students.
DE69902636T2 (de) Verfahren und werkzeuge zur kollektiven herstellung von mikroreliefs, insbesondere von mikroprismen, durch mikrobearbeitung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee